The following is a listing of myeloma treatments associated with this tag.
View all treatments in development for myeloma patients around the US.
Belantamab Mafodotin Blenrep®
Belantamab Mafodotin (formerly GSK2857916) is an antibody-drug conjugate (ADC) directed against the B-cell maturation antigen (BCMA).
SparkCures Verified Accurate, up-to-date information. Learn more
The following is a listing of treatments in development for patients with multiple myeloma who have received one to two prior lines of therapy.
Belantamab Mafodotin Blenrep®
Belantamab Mafodotin (formerly GSK2857916) is an antibody-drug conjugate (ADC) directed against the B-cell maturation antigen (BCMA).
SparkCures Verified Accurate, up-to-date information. Learn more
The following is a listing of treatments in development for patients with multiple myeloma who have received three or more prior lines of therapy.
Belantamab Mafodotin Blenrep®
Belantamab Mafodotin (formerly GSK2857916) is an antibody-drug conjugate (ADC) directed against the B-cell maturation antigen (BCMA).
SparkCures Verified Accurate, up-to-date information. Learn more
The following is a listing of myeloma clinical trials associated with this tag.
View all active clinical trials around the US.
Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma
BELANTAMAB MAFADOTIN MAINTENANCE THERAPY
SparkCures Verified Accurate, up-to-date information. Learn more
A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma
BELANTAMAB MAFODOTIN IN THE COMMUNITY SETTINGA Phase 2 Study of Fludarabine, Cytarabine, Filgrastim-sndz,Gemtuzumab Ozogamicin and Idarubicin in Newly D...
GEMTUZUMAB AS PART OF CHEMOTHERAPYA Pilot Study of Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination With Gemtuzumab Ozogamicin ...
CPX-351 PLUS GEMTUZUMAB OZOGAMICINBelantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
BELANTAMAB MAFODOTIN COMBINATION THERAPYExpanded Access Request Program for Belantamab Mafodotin in Multiple Myeloma
EXPANDED ACCESS REQUEST FOR BELANTAMAB MAFODOTINMinimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autolo...
BELANTAMAB MAFODOTIN OR LENALIDOMIDE MAINTENANCENovel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma
BELANTAMAB MAFODOTIN AND ELOTUZUMABPhase 2 Trial of Belantamab Mafodotin Consolidation Treatment in Patients With Multiple Myeloma and MRD Pos...
BELANTAMAB MAFODOTIN CONSOLIDATIONPhase II Trial for Evaluation of Alternate Doses and Dosing Schedules of Belantamab Mafodotin in Triple-Cla...
DIFFERENT DOSES OF BELANTAMAB MAFODOTINThe following is a listing of clinical trials for patients with multiple myeloma who have been newly diagnosed or have not yet received treatment.
SparkCures Verified Accurate, up-to-date information. Learn more
Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autolo...
BELANTAMAB MAFODOTIN OR LENALIDOMIDE MAINTENANCEPhase 2 Trial of Belantamab Mafodotin Consolidation Treatment in Patients With Multiple Myeloma and MRD Pos...
BELANTAMAB MAFODOTIN CONSOLIDATIONThe following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.
Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma
BELANTAMAB MAFADOTIN MAINTENANCE THERAPYSparkCures Verified Accurate, up-to-date information. Learn more
Phase 2 Trial of Belantamab Mafodotin Consolidation Treatment in Patients With Multiple Myeloma and MRD Pos...
BELANTAMAB MAFODOTIN CONSOLIDATIONThe following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.
Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma
BELANTAMAB MAFADOTIN MAINTENANCE THERAPYSparkCures Verified Accurate, up-to-date information. Learn more
A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma
BELANTAMAB MAFODOTIN IN THE COMMUNITY SETTINGExpanded Access Request Program for Belantamab Mafodotin in Multiple Myeloma
EXPANDED ACCESS REQUEST FOR BELANTAMAB MAFODOTINNovel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma
BELANTAMAB MAFODOTIN AND ELOTUZUMABPhase 2 Trial of Belantamab Mafodotin Consolidation Treatment in Patients With Multiple Myeloma and MRD Pos...
BELANTAMAB MAFODOTIN CONSOLIDATIONPhase II Trial for Evaluation of Alternate Doses and Dosing Schedules of Belantamab Mafodotin in Triple-Cla...
DIFFERENT DOSES OF BELANTAMAB MAFODOTINThe following is a listing of clinical trials for patients with Smoldering Myeloma.
The following is a listing of myeloma tags that are associated with this tag.
B-Cell Maturation Antigen (BCMA)
B-Cell Maturation Antigen (BCMA) is a protein that may be found on the surface of myeloma cells. BCMA may be used as a target to help treatments find and destroy myeloma cells.
CD48
CD48 is a protein that is found on the surface of myeloma cells. This protein may be used as a way for treatments to target and find the myeloma cells.